Speaker
Dr
Sang-Keun Woo
(Korea Institute of Radiological and Medical Sciences)
Description
Purpose:
Evaluation of internal dosimetry should have performed before injection of theranostic radiopharmaceuticals. The aim of this study was to estimate the 64Cu-PSMA-617 biodistribution in mice and human absorbed dose of 64Cu and 225Ac-PSMA-617.
Materials and Methods:
The radiolabeling efficiency of 64Cu-PSMA-617 was showed over 95%, and stabilities of 64Cu-PSMA-617 has remained over 98% in both human and mouse serum for 48 h. 64Cu labeled PSMA-617 were used to calculate the biodistribution in mice (n = 4). Time-dependent biodistribution of 64Cu-PSMA-617 was measured at 2, 4, 6, 24, and 48 hours after injection. Biodistribution data from 64Cu-PSMA-617 in mice were used to calculate residence time and effective dose in human. Human absorbed dose of 64Cu and 225Ac-PSMA-617 was approximated by extrapolation data of 64Cu-PSMA-617 mice biodistribution. Absorbed dose and the effective dose were estimated by the OLINDA/EXM (Vanderbilt University, Nashville, TN) adult male model. Region residence time and absorbed dose have calculated the average with standard deviation (SD).
Results:
The highest uptake ratio was observed in the liver and kidney at 2 h. Rapid blood clearance was observed for 64Cu-PSMA-617. 64Cu-PSMA-617 residence time in liver and kidney were 3.23E+00 ± 3.69E-01 and 3.67E-01 ± 2.67E-02 MBq-h/MBq, respectively. Liver absorbed dose of 64Cu and 225Ac-PSMA-617 were 7.64E-03 ± 8.68E-04 and 2.82E+01 ± 3.24E+00 mGy/MBq, respectively. Kidney absorbed dose of 64Cu and 225Ac-PSMA-617 were 4.61E-04 ± 1.50E-04 and 2.04E+01 ± 1.50E+00 mGy/MBq, respectively. The effective dose of 64Cu and 225Ac-PSMA-617 were 1.77E-02 ± 5.07E-04 and 1.82E+00 ± 1.69E-01 mSv/MBq, respectively.
Conclusion:
We evaluated the human absorbed dose of 64Cu-PSMA-617 and 225Ac-PSMA-617. The 225Ac-PSMA-617 effective dose was 103 fold higher than 64Cu-PSMA-617. These result may help to a strategy of targeted alpha therapy calculate effective dose for metastatic castration-resistant prostate cancer (mCRPC) patients.
| Email Address | skwoo@kirams.re.kr |
|---|---|
| Presentation Type | Poster |
Primary author
Dr
Sang-Keun Woo
(Korea Institute of Radiological and Medical Sciences)
Co-authors
Ms
Ahn Heesu
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Hyeon Park
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Ilhan Lim
(Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Jung Young Kim
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Ki-Hye Jung
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Kyo Chul Lee
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Mr
Sang Jin Han
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Sang Moo Lim
(Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Mr
Wook Kim
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
Dr
Yong Jin Lee
(Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, Korea)
